Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide

J. R. Sheu, T. F. Huang

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.

Original languageEnglish
Pages (from-to)58-62
Number of pages5
JournalJournal of Pharmacy and Pharmacology
Volume46
Issue number1
Publication statusPublished - 1994
Externally publishedYes

Fingerprint

Adenosine Diphosphate
Blood Platelets
Rabbits
Pulmonary Embolism
Platelet Aggregation
Fibrinogen Receptors
Platelet Glycoprotein GPIIb-IIIa Complex
Snake Venoms
Platelet-Rich Plasma
Fibrinolytic Agents
Platelet Count
Fibrinogen
triflavin
arginyl-glycyl-aspartic acid
Peptides
Mortality

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide. / Sheu, J. R.; Huang, T. F.

In: Journal of Pharmacy and Pharmacology, Vol. 46, No. 1, 1994, p. 58-62.

Research output: Contribution to journalArticle

@article{9f81894ad5524d0ebc5b1d9148d02233,
title = "Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide",
abstract = "Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.",
author = "Sheu, {J. R.} and Huang, {T. F.}",
year = "1994",
language = "English",
volume = "46",
pages = "58--62",
journal = "Journal of Pharmacy and Pharmacology",
issn = "0022-3573",
publisher = "Pharmaceutical Press",
number = "1",

}

TY - JOUR

T1 - Ex-vivo and in-vivo antithrombotic effect of triflavin, and RGD-containing peptide

AU - Sheu, J. R.

AU - Huang, T. F.

PY - 1994

Y1 - 1994

N2 - Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.

AB - Triflavin an Arg-Gly-Asp-containing snake venom peptide inhibits platelet aggregation through the blockade of fibrinogen binding to the activated platelets. It binds to fibrinogen receptors associated with the glycoprotein IIb/IIIa complex with a K(d) value of 7 x 10-8 M. In this study we found that 125I-triflavin reached the maximal binding to human platelets within 5 min at 25°C. In addition, when triflavin was intravenously administered at 1.0 mg kg-1 to rabbits it reversibly impaired the platelet aggregation of platelet-rich plasma caused by ADP (20 μM) ex-vivo over 30 min. The platelet counts of the experimental rabbits remained unchanged. Triflavin was effective in reducing the mortality of ADP-induced acute pulmonary thromboembolism in mice when administered intravenously at a dose of 2 μg g-1. Therefore triflavin was proven to be an effective antithrombotic agent in preventing ADP-induced acute pulmonary thromboembolism in mice and impairing reversibly the platelet function of rabbits when given intravenously.

UR - http://www.scopus.com/inward/record.url?scp=0027976903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027976903&partnerID=8YFLogxK

M3 - Article

C2 - 8201528

AN - SCOPUS:0027976903

VL - 46

SP - 58

EP - 62

JO - Journal of Pharmacy and Pharmacology

JF - Journal of Pharmacy and Pharmacology

SN - 0022-3573

IS - 1

ER -